e-learning
resources
Munich 2014
Monday, 08.09.2014
Pulmonary hypertension: novel targets and drugs
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Smooth muscle microparticles as novel biomarkers of vascular remodelling and inflammation in pulmonary arterial hypertension
R. Gurung, L. Clapp, N. Klein (London, United Kingdom)
Source:
International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Session:
Pulmonary hypertension: novel targets and drugs
Session type:
Thematic Poster Session
Number:
2366
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Gurung, L. Clapp, N. Klein (London, United Kingdom). Smooth muscle microparticles as novel biomarkers of vascular remodelling and inflammation in pulmonary arterial hypertension. Eur Respir J 2014; 44: Suppl. 58, 2366
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Endothelial microparticles and progenitor cells in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Skeletal muscle impairment and proteomic profil in human pulmonary arterial hypertension
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014
Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Th17 inflammation and pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Muscle function and physical activity in patients with idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Would RDW be a prognostic factor in pulmonary arterial hypertension?
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Nuclear IL-33 arguments ST2 receptor expression in pulmonary arterial endothelial cells: Implication in the pathogenesis and progression of pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Characterization of circulating CD133+ progenitor cells in pulmonary arterial hypertension
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014
miR-126; link between angiogenesis and exercise intolerance in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Role of NMDA receptors in vascular remodelling associated to pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Cerebral tissue oxygenation in arterial and thromboembolic pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Immune signatures in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Vascular endothelial growth factor (VEGF) as marker of pulmonary hypertension in children with asthma
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Derivation and characterisation of endothelial cells from patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
mir-126 contribute to angiogenesis defect in pulmonary arterial hypertension right ventricle failure
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Obligatory role of MEK/ERK/RSK90 in the mitogenic responses of human pulmonary artery smooth muscle cells
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Non-invasive cardiac output assessment in pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Analysis of pulmonary endothelial microparticles, haemodynamics and functional class in pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Molecular study of genetic modifiers in patients with pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Endothelial-to-mesenchymal transition in pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept